Interventions to achieve tonic exposure to levodopa: Delaying or preventing the onset of motor complications

Pharmacotherapy

Volumn 19, Issue 11 II, 1999, Pages

  Luer, Mark S ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE; LEVODOPA; TOLCAPONE;

AREA UNDER THE CURVE; CONFERENCE PAPER; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DYSKINESIA; ENZYME INHIBITION; HUMAN; MAJOR CLINICAL STUDY; PARKINSON DISEASE; SCORING SYSTEM;

EID: 0032721449     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.17.169s.30886     Document Type: Conference Paper

References (56)

1. Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 1998;55(suppl 1):1-9.
2. Männistö PT, Kaakkola S. Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol Toxicol 1990;66:317-23.
3. LeWitt PA. Levodopa therapeutics: new treatment strategies. Neurology 1993;43(suppl):S31-7.
4. Peppe A, Dambrosia JM, Chase TN. Risk factors for motor response complications in L-dopa-treated parkinsonian patients. Adv Neurol 1993;60:698-702.
5. Fabbrini G, Juncos J, Mouradian MM, Serrati C, Chase TN. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 1987;21:370-6.
6. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part I. Ann Neurol 1988;24:366-71.
7. Koller WC, Rueda MG. Mechanism of action of dopaminergic agents in Parkinson's disease. Neurology 1998;50(suppl 6):S11-14.
8. Papa SM, Engber TM, Kask AM, Chase TN. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 1994;662:69-74.
9. Chase TN, Engber TM, Mouradian MM. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Adv Neurol 1996;69:497-501.
10. Engber TM, Papa SM, Boldry RC, Chase TN. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 1994;5:2586-8.
11. Papa SM, Boldry RC, Engber TM, Kask AM, Chase TN. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res 1995;701:13-18.
12. Mouradian MM, Heuser IJ, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990;27:18-23.
13. Baronti F, Mouradian MM, Davis TL, et al. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Ann Neurol 1992;32:776-81.
14. Block G, Liss C, Reines S, et al. Comparison of immediate-release and controlled-release carbidopa/levodopa in Parkinson's disease: a multicenter 5-year study. Eur Neurol 1997;37:23-7.
15. Yeh KC, August TF, Bush DF, et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 1989;39(suppl 2):25-38.
16. Kurlan R, Lichter D, Miller C, Shoulson I. Combined therapy with controlled-release (CR-4) and standard carbidopa/levodopa for resistant on-off fluctuations in Parkinson's disease. Neurology 1988;38(suppl 1):179.
17. Mark MH, Sage JI. Controlled-release carbidopa/levodopa (Sinemet) in combination with standard Sinemet therapy in advanced Parkinson's disease. Neurology 1988;38(suppl 1):330.
18. Dingemanse J. Catechol-O-methyltransferase inhibitors: clinical potential in the treatment of Parkinson's disease. Drug Dev Res 1997;42:1-25.
19. Guldberg HC, Marsden CA. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev 1975;27:135-206.
20. Nissinen E, Linden IB, Schultz E, Pohto P. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch Pharmacol 1992;346:262-6.
21. Männistö PT, Kaakkola S, Nissinen E, Linden IB, Pohto P. Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase. Life Sci 1988;43:1465-71.
22. Zürcher G, Colzi A, Da Prada M. Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues. J Neural Transm 1990;32(suppl):375-80.
23. Keränen T, Gordin A, Karlsson M, et al. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 1994;46:151-7.
24. Dingemanse J, Jorga KM, Schmitt M, et al. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther 1995;57: 508-17.
25. Roche Laboratories. Tasmar (tolcapone tablets) prescribing information. Nutley, NJ:1998.
26. Jorga K, Dingemanse J, Fotteler B, Zūrcher G. Pharmaco-kinetics-pharmacodynamics of a novel COMT inhibitor during multiple dosing regimens. Clin Pharmacol Ther 1993;53:180.
27. Dingemanse J, Jorga K, Zūrcher G, et al. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol 1996;50:47-55.
28. Da Prada M, Borgulya J, Napolitano A, Zürcher G. Improved therapy of Parkinson's disease with tolcapone, a central and peripheral COMT inhibitor with an S-adenosyl-L-methionine-sparing effect. Clin Neuropharmacol 1994;17(suppl 3): S26-37.
29. Wikberg T, Vuorela A, Ottoila P, Taskinen J. Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab Dispos 1993;21:81-92.
30. Ahtila S, Kaakkola S, Gordin A, et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin Neuropharmacol 1995;18:46-57.
31. Dingemanse J, Jorga K, Zürcher G, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 1995;40:253-62.
32. Sedek G, Leese P, Burns RS, Jorga K, Schmitt M. Effect of COMT inhibition on L-dopa kinetics in the presence of carbidopa. Clin Pharmacol Ther 1993;53:180.
33. Keränen T, Gordin A, Harjola VP, et al. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 1993;16:145-56.
34. Martínez-Martin P, O'Brien CF. Extending levodopa action: COMT inhibition. Neurology 1998;50(suppl 6):S27-32.
35. Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 1996;60:36-40.
36. Kaakkola S, Teräväinen H, Ahtila S, Rita H, Gordin A. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 1994;44:77-80.
37. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-19.
38. Sedek G, Jorga K, Schmitt M, Burns RS, Leese P. Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers. Clin Neuropharmacol 1997;20:531-41.
39. Napolitano A, Del Dotto P, Petrozzi L, et al. Pharmacokinetics and pharmacodynamics of L-dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease. Clin Neuropharmacol 1999;22:24-9.
40. Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1993;43:2685-8.
41. Limousin P, Pollak P, Pfefen JP, Tournier-Gervason CL, Dubuis R, Perret JE. Acute administration of levodopabenserazide and tolcapone, a COMT inhibitor, in Parkinson's disease. Clin Neuropharmacol 1995;18:258-65.
42. Yamamoto M, Yokochi M, Kuno S, et al. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease. J Neural Transm 1997;104:229-36.
43. Ruottinen HM, Rinne UK. COMT inhibition in the treatment of Parkinson's disease. J Neurol 1998;245(suppl 3):25-34.
44. Rinne UK, Larsen JP, Siden A, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 1998;51:1309-14.
45. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747-55.
46. Rajput AH, Martin W, Saint-Hilaire M-H, Dorflinger E, Pedder S. Tolcapone improves motor functions in parkinsonian patients with the wearing off phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997;49:1066-71.
47. Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyl-transferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997;63:421-8.
48. Waters CH, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Neurology 1997;49:665-71.
49. Assal F, Spahr L, Hadengue A, Rubbici-Brandt L, Burkhard PR. Tolcapone and fulminant hepatitis [letter]. Lancet 1998;352:958. Erratum appears in Lancet 1998;352:1478.
50. Anonymous. Roche Tasmar more frequent liver monitoring urged in EU label revision. FDC Rep Pink Sheet 1998; 60(42):17.
51. Anonymous. Roche Tasmar relabeling adds patient consent form citing liver toxicity. FDC Rep Pink Sheet 1998;60(47): 21-2.
52. Illi A, Sundberg S, Ojala-Karlsson P, Korhonen P, Scheinin M, Gordin A. The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine. Clin Pharmacol Ther 1995;58:221-7.
53. Illi A, Sundberg S, Ojala-Karlsson P, Scheinin M, Gordin A. Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine: lack of interactions. Eur J Clin Pharmacol 1996;51:273-6.
54. Illi A, Sundberg S, Ojala-Karlsson P, Scheinin M, Gordin A. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers. Clin Pharmacol Ther 1996;59:450-7.
55. Sedek G, Jorga K, Yoo K, Hood J. Lack of interaction between ephedrine and combination of tolcapone and Sinemet. Neurology 1996;46(suppl):A374.
56. Sundberg S, Gordin A. COMT inhibition with nitecapone does not affect the tyramine pressor response. Br J Clin Pharmacol 1991;32:130-2.